BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment
and supportive care of cancer and AIDS patients, today announces final
positive results of its pivotal phase III clinical study in
immunocompetent patients with recurrent herpes labialis (LIP Study)
treated with acyclovir Lauriad®. Primary and secondary
endpoints have been met with marked efficacy and good tolerance.
This international multicenter randomized, double-blind,
placebo-controlled study compared the efficacy and safety of a single
dose of acyclovir Lauriad® 50mg Mucoadhesive Buccal Tablet
(MBT) versus matching placebo in 1727 randomized and 775 treated
patients suffering from recurrent herpes labialis.
A single dose of acyclovir Lauriad® 50mg MBT significantly
reduced the time to healing of primary vesicular lesion>
Among patients who accepted to be followed for 9 months after this
single administration of treatment, the time to recurrence to the next
herpes episode was markedly delayed after the application of acyclovir
Lauriad® 50mg MBT (37 days delay versus placebo,>
Finally, acyclovir Lauriad® 50mg MBT was extremely well
tolerated with very minor side effects, comparable to those observed
with placebo, in particular diarrhea, headache, and local irritation
were rare in contrast to systemic or topical treatments.